ArticleAnalytical chemistry2017
Toward an Optimized Workflow for Middle-Down Proteomics.
Article in Analytical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 125 citations in OpenAlex.
- Top-Down Mass Spectrometry and Its Current Applications in Biomarker Discovery in Aging and Age-Related Diseases.International journal of molecular sciences · 2026Review
- Enhancing Proteoform Sequence Coverage Using Top-Down Mass Spectrometry with In-Source Fragmentation and Middle-Down Mass Spectrometry.Analytical chemistry · 2026Article
- Review
- Sample Preparation for Multi-Omics Analysis: Considerations and Guidance for Identifying the Ideal Workflow.Proteomics · 2025Review
- PEPPI-MS: gel-based sample pre-fractionation for deep top-down and middle-down proteomics.Nature protocols · 2025Review
- Strategies for Acid and Amine Cross-linking and Labeling for Protein Structural Characterization Using Mass Spectrometry.Analytical chemistry · 2025Article
- The Enzyme Effect: Broadening the Horizon of MS Optimization to Nontryptic Digestion in Proteomics.Journal of the American Society for Mass Spectrometry · 2025Article
- Digital Microfluidics for Sample Preparation in Low-Input Proteomics.Small methods · 2025Review
- Protein isoform-centric therapeutics: expanding targets and increasing specificity.Nature reviews. Drug discovery · 2024Review
- Computational approaches to identify sites of phosphorylation.Proteomics · 2024Review
- The Shelf Life of Milk-A Novel Concept for the Identification of Marker Peptides Using Multivariate Analysis.Foods (Basel, Switzerland) · 2024Article
- Decoding Ubiquitin Modifications by Mass Spectrometry.Advances in experimental medicine and biology · 2024Review
- Mass Spectrometry-Based Proteomics: Analyses Related to Drug-Resistance and Disease Biomarkers.Medicina (Kaunas, Lithuania) · 2023Review
- Affi-BAMS™: A Robust Targeted Proteomics Microarray Platform to Measure Histone Post-Translational Modifications.International journal of molecular sciences · 2023Article
- Article
- Identification of Marker Peptides for the Whey Protein Quantification in Edam-Type Cheese.Foods (Basel, Switzerland) · 2023Article
- Review
- Proteoforms expand the world of microproteins and short open reading frame-encoded peptides.iScience · 2023Review
- Middle-Down Mass Spectrometry Reveals Activity-Modifying Phosphorylation Barcode in a Class C G Protein-Coupled Receptor.Journal of the American Chemical Society · 2022Article
- Post-Translational Modifications of Histones Are Versatile Regulators of Fungal Development and Secondary Metabolism.Toxins · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass spectrometry (MS)-based proteomics workflows can crudely be classified into two distinct regimes, targeting either relatively small peptides (i.e., 0.7 kDa < M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.